BioCentury | Jul 25, 2020
Finance

Preclinical IPOs attracting big money, but yet to see exponential growth of clinical peers

An analysis of preclinical IPO performance since the window opened eight years ago shows the companies have done about as well as their clinical peers. What’s missing are standout examples of explosive growth, though those...
BioCentury | Jun 13, 2020
Product Development

Additional durability data build confidence for gene editing, gene therapies in hemoglobinopathies

It’s all about durability for gene therapies and gene editing treatments in hemoglobinopathies, and new data suggest programs from partners CRISPR Therapeutics and Vertex as well as bluebird are on track to deliver. In addition...
BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

A pair of CNS approvals in the final days of 2019 has only added to the growing momentum buysiders were already tracking for 2020 in the once neglected disease area. Positive regulatory signals are converging...
BioCentury | Dec 11, 2019
Tools & Techniques

Editas shows better gene editing using Cas9 alternative for sickle cell, thalassemia

Editas is using an alternative to Cas9 to develop a differentiated sickle cell and β thalassemia CRISPR gene therapy. Preclinical data presented Monday at ASH suggest that ex vivo gene editing could be more effective...
BioCentury | Nov 22, 2019
Financial News

Follow-on roundup: Karuna, CRISPR, Molecular Therapeutics, OptiNose

Since market close on Wednesday, Karuna, CRISPR Therapeutics, Molecular Therapeutics and OptiNose have raised an aggregate of more than $600 million in follow-ons. Karuna Therapeutics Inc. (NASDAQ:KRTX) raised $250 million late Wednesday through the sale...
BioCentury | Nov 19, 2019
Company News

Vertex, Molecular Templates partner to improve conditioning regimens for edited cell therapies

Vertex is collaborating with Molecular Templates to establish more targeted conditioning regimens that could replace chemotherapy in patients undergoing hematopoietic stem cell transplants. Under the deal, Molecular Templates Inc. (NASDAQ:MTEM) will use its engineered toxin...
BioCentury | Nov 19, 2019
Clinical News

Vertex, CRISPR show early benefits with therapy, but longer term data are needed to show how it stacks up

Vertex and partner CRISPR Therapeutics showed sustained benefits in the first two patients treated with their CTX001, but longer term data will be needed to understand how the ex vivo CRISPR therapy stacks up against...
BioCentury | Nov 11, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

As new therapies designed to cut off sickle cell disease pathology at the root advance through the clinic, the field is moving beyond endpoints centered on pain crises to readouts based on hemoglobin. A single,...
BioCentury | Nov 9, 2019
Product Development

Sickle cell disease poised for fresh infusion of hemoglobin-based endpoints

As new therapies designed to cut off sickle cell disease pathology at the root advance through the clinic, the field is moving beyond endpoints centered on pain crises to readouts based on hemoglobin. A single,...
Items per page:
1 - 10 of 35